Fernand Labrie
Publications
Page 4 of 8, showing 50 records out of 368 total, starting on record 151, ending on 200
| Publication | Category | Year |
|---|---|---|
| 4708. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 | Prostate Cancer | 2010 |
| 32. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. | Prostate Cancer | 2003 |
| 29. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. | Prostate Cancer | 2004 |
| 89. Simard, J., Labrie, F. (1997) Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy, in: New diagnostic and treatment modalities in prostate cancer, Project in Knowledge, pp 15-23. | Prostate Cancer | 1997 |
| 90. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. | Prostate Cancer | 1997 |
| 162. Simard, J., Veilleux, R., de Launoit, Y., Haagensen, D.E., Labrie, F. (1991) Stimulation of apoliprotein D secretion by steroids coincide with inhibition of cell proliferation in LNCaP prostate cancer cells. Cancer Res., 51: 4336-4341. | Prostate Cancer | 1991 |
| 54. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. | Prostate Cancer | 2000 |
| 4683. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. | Prostate Cancer | 2009 |
| 130. Sugimoto, K., Simard, J., Veilleux, R., Haagensen, D.E., Labrie, F. (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J. Steroid Biochem. Mol. Biol., 51: 167-174. | Prostate Cancer | 1994 |
| 120. Sun, S., Narod, S., Aprikian, A., Ghadirian, P., Labrie, F. (1995) Androgen receptor and familial prostate cancer. Nature Medicine, 1: 848-849. | Prostate Cancer | 1995 |
| 10. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. | Prostate Cancer | 2007 |
| 11. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. | Prostate Cancer | 2007 |
| 163. Têtu, B., Srigley, J.R., Boivin, J.C., Dupont, A., Monfette, G., Pinault, S., Labrie, F. (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am. J. Surg. Pathol., 15: 111-120. | Prostate Cancer | 1991 |
| 79. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. | Prostate Cancer | 1998 |
| 18. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. | Prostate Cancer | 2006 |
| 12. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. | Prostate Cancer | 2007 |
| 43. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. | Prostate Cancer | 2001 |
| 13. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. | Prostate Cancer | 2007 |
| 106. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. | Prostate Cancer | 1996 |
| 107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. | Prostate Cancer | 1996 |
| 14. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. | Prostate Cancer | 2007 |
| 55. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. | Prostate Cancer | 2000 |
| 349. Asselin, J., Labrie, F., Gourdeau, Y., Bonne, C., Raynaud, J.P. (1976) Binding of [3H]methyltrienolone (Rl88l) in rat prostate and human benign prostatic hypertrophy (BPH). Steroids, 28: 449-459. | Prostate Cancer | 1976 |
| 342. Auclair, C., Cusan, L., Kledzik, G.S., Ferland, L., Kelly, P.A., Labrie, F. (1978) Inhibition de fonctions gonadiques par la LHRH et ses agonistes chez le rat mâle et femelle. Union Med. Can., 107: 356-364. | Prostate Cancer | 1978 |
| 343. Auclair, C., Ferland, L., Cusan, L., Kelly, P.A., Labrie, F., Azadian-Boulanger, G., Raynaud, J.P. (1978) Effet inhibiteur de la LHRH sur les récepteurs de la LH dans le testicule chez le rat. C.R. Acad. Sci. Hebd. Seances Acad. Sci. D, 286: 1305-1307. | Prostate Cancer | 1978 |
| 346. Auclair, C., Kelly, P.A., Coy, D.H., Schally, A.V., Labrie, F. (1977) Potent inhibitory activity of [D-Leu6, des-Gly-NH2 10]ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology, 101: 1890-1893. | Prostate Cancer | 1977 |
| 347. Auclair, C., Kelly, P.A., Labrie, F., Coy, D.H., Schally, A.V. (1977) Inhibition of testicular LH/hCG receptor level by treatment with a potent LHRH agonist or hCG. Biochem. Biophys. Res. Commun., 76: 855-862. | Prostate Cancer | 1977 |
| 199. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. | Prostate Cancer | 1988 |
| 330. Bélanger, A., Auclair, C., Ferland, L., Caron, S., Labrie, F. (1980) Time-course of the effect of treatment with a potent LHRH agonist on testicular steroidogenesis and gonadotropin receptor levels in the adult rat. J. Steroid Biochem., 13: 191-196. | Prostate Cancer | 1980 |
| 318. Bélanger, A., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1981) Prolactin stimulation of testicular steroid biosynthesis in the male rat. J. Androl., 2: 80-86. | Prostate Cancer | 1981 |
| 338. Bélanger, A., Auclair, C., Séguin, C., Kelly, P.A., Labrie, F. (1979) Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin. Mol. Cell. Endocrinol., 13: 47-53. | Prostate Cancer | 1979 |
| 319. Bélanger, A., Caron, S., Cusan, L., Séguin, C., Auclair, C., Labrie, F. (1981) Inhibition of testicular androgen biosynthesis by treatment with LHRH agonists, in: McKerns, K.W., ed. Reproductive Processes and Contraception. International Society for Biochemical Endocrinology, New York, Plenum Press, pp 471-491. | Prostate Cancer | 1981 |
| 331. Bélanger, A., Cusan, L., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1980) Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult rat. Biol. Reprod., 22: 1094-1101. | Prostate Cancer | 1980 |
| 332. Bélanger, A., Cusan, L., Séguin, C., Caron, S., Labrie, F. (1980) Inhibition de la stéroïdogénèse testiculaire chez le rat par traitement avec un agoniste de la LHRH. Union Med. Can., 109: 489-494. | Prostate Cancer | 1980 |
| 280. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. | Prostate Cancer | 1984 |
| 200. Bélanger, A., Giasson, M., Cliche, J., Dupont, A., Labrie, F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84. | Prostate Cancer | 1988 |
| 201. Belanger, A., Labrie, F., Dupont, A., Brochu, M., Cusan, L. (1988) Endocrine effects of combined treatment with an LHRH agonist in association with Flutamide in metastatic prostatic carcinoma. Clin. Invest. Med., 11: 321-326. | Prostate Cancer | 1988 |
| 333. Belanger, A., Labrie, F., Lemay, A., Caron, S., Raynaud, J.P. (1980) Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly -NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men. J. Steroid Biochem., 13: 123-126. | Prostate Cancer | 1980 |
| 302. Bélanger, A., Labrie, F., Séguin, C., Cusan, L., Carmichael, R., Caron, S. (1983) Inhibition of testicular delta 4-androgen secretion in the rat by treatment with luteinizing hormone-releasing hormone, in: Negro-Vilar, A., ed. Male Reproduction and Fertility, New York, Raven Press, pp 127-139. | Prostate Cancer | 1983 |
| 281. Bélanger, A., Tremblay, Y., Lacoste, D., Giasson, M., Dupont, A., Labrie, F. (1984) The dog, a good model for the study of LHRH agonists as blockers of androgen secretion and potential contraceptives, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its Analogues: Basic and Clinical Aspects, New York, Excerpta Medica, pp 141-155. | Prostate Cancer | 1984 |
| 229. Brochu, M., Bélanger, A., Dupont, A., Cusan, L., Labrie, F. (1987) Effects of Flutamide and aminoglutethimide on plasma 5?-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J. Steroid Biochem., 28: 619-622. | Prostate Cancer | 1987 |
| 1. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. | Prostate Cancer | 2009 |
| 311. Carmichael, R., Bélanger, A., Caron, S., Labrie, F., Sairam, M.R. (1982) Comparative effects of LHRH agonist and ovine LH administration on testicular steroidogenesis in intact adult rat. Steroids, 40: 641-649. | Prostate Cancer | 1982 |
| 73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. | Prostate Cancer | 1998 |
| 350. Coy, D.H., Labrie, F., Savary, M., Coy, E.J., Schally, A.V. (1976) Antagonistic activity of analogs of luteinizing hormone-releasing hormone (LHRH) in vitro. Mol. Cell. Endocrinol., 5: 201-208. | Prostate Cancer | 1976 |
| 339. Cusan, L., Auclair, C., Bélanger, A., Ferland, L., Kelly, P.A., Séguin, C., Labrie, F. (1979) Inhibitory effects of long-term treatment with an LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology, 104: 1369-1376. | Prostate Cancer | 1979 |
| 230. Dubé, D., Assaf, A., Pelletier, G., Labrie, F. (1987) Morphological study of the effects of an GnRH agonist on the canine testis after 4 months of treatment and recovery. Acta Endocrinol. (Copenh.), 116: 413-417. | Prostate Cancer | 1987 |
| 231. Dubé, D., Pelletier, G., Labrie, F. (1987) Morphological studies of the canine pituitary LH cells after long-term treatment with the LHRH agonist [D-Trp6]LHRH ethylamide. Endocrinology, 120: 589-594. | Prostate Cancer | 1987 |
| 202. Dubé, D., Pelletier, G., Labrie, F. (1988) The luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6-des-Gly-NH2(10)]-LHRH ethylamide has no direct effect on spermatogenesis in the rat. Biol. Reprod., 38: 1165-1170. | Prostate Cancer | 1988 |
| 249. Dubé, D., Poyet, P., Pelletier, G., Labrie, F. (1986) Radioautographic localization of ?-adrenergic receptors in the rat ventral prostate. J. Androl., 7: 169-174. | Prostate Cancer | 1986 |